scriptaid

Scriptaid is a small molecule histone deacetylase (HDAC) inhibitor that was one of the first compounds discovered via high-throughput screening to act at this target. It is a cell-permeable hydroxamic acid derivative with relatively low toxicity. Scriptaid has been primarily researched for its anti-tumor properties and as a radiosensitizer in cancer models, where it enhances the response of tumor cells to radiation by inhibiting DNA double-strand break repair and suppressing Ku80 expression. While not developed for clinical use itself, it has served as a lead compound for the development of other HDAC inhibitors such as vorinostat. Beyond oncology research, Scriptaid has also been used in studies related to cloning and metabolic regulation[1][2][4][6].

Other names

scriptaidScriptide287383-59-96-(1,3-Dioxo-1H-benzo[de]isoquinolin-2(3H)-yl)-N-hydroxyhexanamideN-Hydroxy-1,3-dioxo-1H-benz(de)isoquinoline-2(3H)-hexan amide